San Diego, CA -- (SBWIRE) -- 11/09/2016 -- Diplomat Pharmacy Inc is under investigation over possible violations of securities laws. The investigation was announced for investors in NYSE:DPLO shares in connection certain financial statements made by Diplomat Pharmacy Inc.

Investors who purchased shares of Diplomat Pharmacy Inc (NYSE:DPLO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether a series of statements by Diplomat Pharmacy Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On November 2, 2016, Diplomat Pharmacy Inc reported third quarter 2016 results. Diplomat Pharmacy Inc also lowered full year 2016 guidance, with the CEO and Chairman commenting, "We are disappointed with our third quarter results, which were significantly impacted by the softness in the hepatitis C business nationwide, as well as by DIR fees. The methodology and transparency around how PBMs are applying these DIR fees changed materially in 2016, and while we cannot reverse the impact they had on this quarter, we are working with our partners in the specialty pharmacy industry and with legislators to achieve an amicable solution to this problem." Shares of Diplomat Pharmacy Inc (NYSE:DPLO) declined to as low as $12.47 per share on November 4, 2016.

On November 8, 2016, NYSE:DPLO shares closed at $13.73 per share.

Those who purchased shares of Diplomat Pharmacy Inc have certain options and should contact the Shareholders Foundation.